



November 30, 2016

Arena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference

SAN DIEGO, Nov. 30, 2016 /PRNewswire/ -- [Arena Pharmaceuticals, Inc.](#) (NASDAQ: ARNA) today announced that four abstracts will be presented at the [2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference](#) on Friday, December 9 at 6:00pm ET. The conference is taking place December 8-10 at the Walt Disney World Dolphin Hotel in Orlando, Florida. The data will also be published in the February issue of the [Inflammatory Bowel Diseases Journal](#), a peer-reviewed medical journal bringing the most current information in clinical and basic sciences to physicians caring for patients with inflammatory bowel diseases (IBD), and investigators performing research in IBD and related fields.

The following abstracts will be presented:

Title: *Preclinical Safety Assessment of Etrasimod (APD334), an Oral Sphingosine-1-Phosphate Receptor (S1P) Modulator with a Unique Profile*

Session Type: Poster Presentation

Poster Board Number: P-250

Date: Friday, December 9 at 6:00pm-7:00pm ET

Location: Exhibit Hall - Atlantic B-C

Title: *The Sphingosine-1-Phosphate Receptor (S1P) Modulator Etrasimod (APD334) Demonstrates Limited Effects on Heart Rate in Preclinical Testing*

Session Type: Poster Presentation

Poster Board Number: P-261

Date: Friday, December 9 at 6:00pm-7:00pm ET

Location: Exhibit Hall - Atlantic B-C

Title: *Safety, Pharmacokinetics and Pharmacodynamics of Etrasimod (APD334), an Oral Selective S1P Receptor Modulator, after Single Dose Escalation, in Healthy Volunteers*

Session Type: Poster Presentation

Poster Board Number: P-179

Date: Friday, December 9 at 6:00pm-7:00pm ET

Location: Exhibit Hall - Atlantic B-C

Title: *Etrasimod (APD334), a Potent, Selective, Oral S1P Receptor Modulator With Autoimmune Disease-Modifying Activity that Exhibits Favorable PK/PD Properties in Healthy Volunteers*

Session Type: Poster Presentation

Poster Board Number: P-180

Date: Friday, December 9 at 6:00pm-7:00pm ET

Location: Exhibit Hall - Atlantic B-C

About Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas. We have three primary proprietary investigational [clinical programs](#): [etrasimod](#) (APD334) in Phase 2 evaluation for ulcerative colitis, [APD371](#) entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and [ralinepag](#) (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH). Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentation; the publication of the data; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc.
Kevin R. Lind, Chief Financial Officer
klind@arenapharm.com
858.210.3636

Logo - <http://photos.prnewswire.com/prnh/20161107/436843LOGO>

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-four-upcoming-presentations-at-the-2016-advances-in-inflammatory-bowel-diseases-crohns--colitis-foundations-clinical-and-research-conference-300370082.html>

SOURCE Arena Pharmaceuticals, Inc.

News Provided by Acquire Media